Activation of type-2 chloride channels: A novel therapeutic target for the treatment of chronic constipation

Current Opinion in Investigational Drugs

Volumn 8, Issue 1, 2007, Pages 66-70

  Crowell, Michael D ^a   Harris, Lucinda A ^a   DiBaise, John K ^a   Olden, Kevin W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chloride channel; Clinical trial; Constipation; Lubiprostone; Type 2 chloride channel

Indexed keywords

CHLORIDE CHANNEL; LACTULOSE; LUBIPROSTONE; MACROGOL; MACROGOL 3350; PLACEBO; SEROTONIN 4 RECEPTOR; TEGASEROD;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; APICAL MEMBRANE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ELIMINATION; FLATULENCE; HEADACHE; HUMAN; INTESTINE EPITHELIUM CELL; INTESTINE FUNCTION; NAUSEA; PRESCRIPTION; QUALITY OF LIFE; REVIEW; VOMITING;

ALPROSTADIL; CHLORIDE CHANNELS; CHRONIC DISEASE; CONSTIPATION; DIARRHEA; FATTY ACIDS; HUMANS; MODELS, BIOLOGICAL; NAUSEA; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33947319482     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Wald A: Diagnosis of constipation in primary and secondary care. Rev Gastroenterol Disord (2004) 4(Suppl 2):S28-S33.
2. Talley NJ: Management of chronic constipation. Rev Gastroenterol Disord (2004) 4(1):18-24.
3. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ: Systematic review on the management of chronic constipation in North America. Am J Gastroenterol (2005) 100(Suppl 1):S5-S21. ••; An important, evidence-based monograph on the management of chronic constipation in North America. The monograph provides an evidence-based review and graded recommendations regarding the appropriate diagnosis and treatment of chronic constipation.
4. Higgins PD, Johanson JF: Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol (2004) 99(4):750-759.
5. Glia, A, Lindberg G: Quality of life in patients with different types of functional constipation. Scand J Gastroenterol (1997) 32(11):1083-1089.
6. Irvine EJ, Ferazzi S, Pare P, Thompson WG, Rance L: Health-related quality of life in functional GI disorders: Focus on constipation and resource utilization. Am J Gastroenterol (2002) 97(8):1986-1993.
7. Johanson JF, Sonnenberg A, Koch TR: Clinical epidemiology of chronic constipation. J Clin Gastroenterol (1989) 11(5):525-536.
8. Lembo A, Camilleri M: Chronic constipation. N Engl J Med (2003) 349(14):1360-1368.
9. Schiller LR, Dennis E, Toth G: An Internet-based survey of the prevalence and symptom spectrum of chronic constipation. Am J Gastroenterol (2004) 99(Suppl):Abs 723.
10. Schiller, LR, Dennis E, Toth G: Primary care physicians consider constipation as a severe and bothersome medical condition that negatively impacts patients' lives. Am J Gastroenterol (2004) 99(Suppl):Abs 724.
11. Package insert: MiraLax. Braintree Laboratories Inc, Braintree, MA, USA (2001).
12. Montrose MH, Keely SJ, Barrett KE: Electrolyte secretion and absorption: Small intestine and colon. In: Textbook of Gastroenterology, 3rd Edition. Yamada T, Alpers DH, Laine L, Ow Yang CM, Powell DW (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (1999) 1:320-355.
13. Barrett KE, Keely SJ: Chloride secretion by the intestinal epithelium: Molecular basis and regulatory aspects. Annu Rev Physiol (2000) 62:535-572.
14. Begenisich T, Melvin JE: Regulation of chloride channels in secretory epithelia. J Membr Biol (1998) 163(2):77-85.
15. Lipecka J, Bali M, Thomas A, Fanen P, Edelman A, Fritsch J: Distribution of the ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol (2002) 282(4):C805-C816.
16. Gyömörey K, Yeger H, Ackerley C, Garami E, Bear CE: Expression of the chloride channel ClC-2 in the murine small intestine epithelium. Am J Physiol Cell Physiol (2000) 279(6):C1787- C1794.
17. Catalán M, Cornejo I, Figueroa CD, Niemeyer MI, Sepúlveda FV, Cid LP: ClC-2 in guinea pig colon: mRNA, immunolabeling, and functional evidence for surface epithelium localization. Am J Physiol Gastrointest Liver Physiol (2002) 283(4):G1004-G1013.
18. - transport in human tissues.
19. - in the basolateral membranes of the distal colon which could provide a crosstalk mechanism to match fluxes at the apical and basolateral domains of these epithelial cells.
20. Ueno R, Osama H, Habe T, Engelke K, Patchen M: Oral SPI-0211 increases intestinal fluid secretion and chloride concentrations without altering serum electrolyte levels. Gastroenterology (2004) 126(Suppl 2):A298.
21. Package insert: Amitiza. Sucampo Pharmaceuticals Inc, Bethesda, MD, USA (2006).
22. Orr KK: Lubiprostone: A novel chloride channel activator for the treatment of constipation. Formulary (2006) 41:118-129.
23. Camilleri M, Bharucha A, Ueno R, Burton D, Thomforde GM, Baxter K, McKinzie S, Zinsmeister AR: Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 290(5):G942-G947. •• This study demonstrated the important pharmacodynamic effects of lubiprostone in the human gastrointestinal tract.
24. Johanson JF, Gargano MA, Patchen ML, Ueno R: Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation. Gastroenterology (2002) 122(Suppl 1):A315.
25. Johanson JF, Gargano MA, Patchen ML, Ueno R: Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology (2003) 124(Suppl 1):A48.
26. Johanson JF, Gargano MA, Patchen ML, Ueno R: Phase III study of lubiprostone, a chloride channel-2 (CIC-2) activator for treatment of constipation: Safety and primary efficacy. Am J Gastroenterol (2005) 100(Suppl 7):S328.
27. Johanson JF, Gargano MA, Patchen ML, Ueno R: Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology (2004) 126(Suppl 2):S100.
28. Ueno R, Panas R, Wahle A, Zhu Y, Holland PC: Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterology (2006) 130(4 Suppl 2):A188.
29. Johanson JF, Gargano MA, Patchen ML, Ueno R: Multi-center open-label study of lubiprostone for the treatment of chronic constipation. Am J Gastroenterol (2005) 100(Suppl 7):S331.
30. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R: Phase III efficacy and safety of RU-0211, a novel chloride channel activator for the treatment of constipation. Am J Gastroenterology (2003) 124:Abs 372.
31. Johanson JF, Gargano MA, Holland PC, Patchen ML, Ueno R: Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: Safety and primary efficacy. Am J Gastroenterology (2005) 100(9 Suppl):S328-S329.